department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Imdelltra · pharmadog

pharmadog
drugs
Imdelltra

drug

patient view →

tarlatamab

Marketedupdated 2mo ago

by $AMGN AMGEN INC

Approved

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

all catalysts(2)

approval · 2

IMDELLTRA (TARLATAMAB-DLLE) — FDA approval

IMDELLTRA (TARLATAMAB-DLLE) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Imdelltra

generic

tarlatamab-dlle

MOA

12.1 Mechanism of Action Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC.

indication

Small-Cell Lung Cancer

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$AMGN366.44-2.06%

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$AMGN366.44-2.06%

🐶 often sniffed alongside

top 3

drugIMDELLTRA8 co-mentions · 2 sources
tagApproval8 co-mentions · 2 sources
company$AMGNAMGEN INC4 co-mentions · 2 sources

Trials studying tarlatamab

phase2A Study of Tarlatamab for People With Prostate Cancerrecruitingn=32
phase3A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)recruitingn=330
phase2Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumorsrecruitingn=70
phase1Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)active not recruitingn=200
phase2A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2recruitingn=48
phase3Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)recruitingn=400
phase2Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatmentactive not recruitingn=32
phase1Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)not yet recruitingn=160

more trials →